Corcept Therapeutics (CORT) Work In Process (2012 - 2026)
Corcept Therapeutics (CORT) posted Work In Process of $18.9 million for Q2 2026, up 60.16% sequentially from $11.8 million in Q1 2026, and up 60.31% YoY from $11.8 million in Q2 2025.
Corcept Therapeutics (CORT) Work In Process (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Work In Process for 15 years, with the latest figure at $18.9 million in Q2 2026.
- Quarterly Work In Process rose 60.31% year-over-year to $18.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.9 million (up 60.31% YoY) and the FY2025 annual result came in at $13.7 million, up 75.93% from the prior year.
- Work In Process advanced to $18.9 million in Q2 2026 per CORT's latest filing, from $11.8 million in the prior quarter.
- Over five years, Work In Process peaked at $18.9 million in Q2 2026 and troughed at $6.7 million in Q2 2023.
- A 5-year average of $10.2 million and a median of $8.6 million in 2023 frame the typical range for Work In Process.
- The sharpest annual moves came in 2023 and 2025: Work In Process tumbled 41.28% in 2023, then soared 82.86% in 2025.
- Over 5 years, Work In Process stood at $7.8 million in 2022, then rose by 5.19% to $8.2 million in 2023, then retreated by 5.39% to $7.8 million in 2024, then surged by 75.93% to $13.7 million in 2025, then surged by 38.02% to $18.9 million in 2026.
- According to Business Quant data, Work In Process over the past three periods registered $18.9 million, $11.8 million, and $13.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.91 Mn |
| Mar 31, 2026 | 11.81 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 14.20 Mn |
| Jun 30, 2025 | 11.80 Mn |
| Mar 31, 2025 | 7.04 Mn |
| Dec 31, 2024 | 7.79 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 8.45 Mn |
| Mar 31, 2024 | 7.13 Mn |
| Dec 31, 2023 | 8.23 Mn |
| Sep 30, 2023 | 8.74 Mn |
| Jun 30, 2023 | 6.68 Mn |
| Mar 31, 2023 | 8.51 Mn |
| Dec 31, 2022 | 7.83 Mn |
| Sep 30, 2022 | 11.17 Mn |
| Jun 30, 2022 | 11.37 Mn |
| Mar 31, 2022 | 12.64 Mn |
| Dec 31, 2021 | 11.45 Mn |
| Sep 30, 2021 | 13.73 Mn |